Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172041 | 0.85 | POLB (0.51) | MAPTPOLBALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4717711 | 0.85 | SIRT6 (0.59) | MAPTPOLBALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL28720277 | 0.84 | POLB (0.46) | MAPTPOLBALDH1A1LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL3258109 | 0.84 | ADRB1 (0.58) | MAPTPOLBALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL2561915 | 0.79 | TDP1 (0.54) | MAPTPOLBALDH1A1CYP2C19 | |
| SCHEMBL24269699 | 0.79 | MAPT (0.54) | MAPTALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL29547961 | 0.79 | MAPT (0.54) | MAPTALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL12325547 | 0.79 | TSHR (0.57) | MAPTALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL31248799 | 0.79 | MAPT (0.54) | MAPTALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL5598235 | 0.79 | MAPT (0.59) | MAPTPOLBALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772432-B2 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-08-10 | — | — | US | disclosed |
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | ASTRAZENECA | 2005-02-17 | — | — | US | disclosed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | disclosed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038081-A1 | Amidobenzamide derivatives which are useful as cytokine inhibitors | IL6, IL6ST, IL2 | MAPT 4659/4885POLB 2834/4885ALDH1A1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.